Skip to content
OpenCapital
Get started

EXOZ EXOZ Second Licensed Product — Cumulative Net Sales

Similar metrics at other companies

Lexicon Pharmaceuticals logo
LXRXLicense — Net product and licensing revenue
$20M—
Lexicon Pharmaceuticals logo
LXRXProduct — Net product and licensing revenue
$1.09M-13.6%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Pacira BioSciences, Inc. logo
PCRXNet product sales — Total net product sales
$177.38M+5.8%
CorMedix logo
CRMDProduct sales, net — Total Revenue
$121.92M+212%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%

Other financials

Income statement

See full
Revenue$17.5K—
Operating income-$2.4M-22.4%
Net income-$2.4M-27.7%
EPS (diluted)-$0.28-27.3%

Balance sheet

See full
Cash & equivalents$1.4M-83.0%
Total debt$1.2M-8.8%
Total equity$1.5M-82.8%
Total assets$4.0M-65.1%

Cash flow

See full
Operating cash flow-$1.5M-34.5%
CapEx$57.6K+85.5%
Free cash flow-$1.6M-35.8%

Valuation

See full
Market cap$76.8M-5.6%
Enterprise value$76.57M+1.0%
P/S1,096.1×—

Profitability

See full
Operating margin-14,489.6%—
Net margin-2,909.1%—
FCF margin-10,117.8%—

Returns & leverage

See full
Return on equity-185.8%—
Debt / equity0.8×+0.6×
Current ratio1.3×-5.2×

Where this comes from

Reported directly by EXOZ in its filing.

Tagged under the XBRL concept EXOZ:CumulativeNetSales.

The official record: EXOZ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about EXOZ's second licensed product — cumulative net sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EXOZ's second licensed product — cumulative net sales?
EXOZ (EXOZ) reported second licensed product — cumulative net sales of $2M in Q1 2026.
How has EXOZ's second licensed product — cumulative net sales changed year-over-year?
EXOZ's second licensed product — cumulative net sales decreased by 0.0% year-over-year, from $2M to $2M.
What does second licensed product — cumulative net sales mean?
This metric tracks the total historical revenue generated from a specific licensed product since its commercial launch or inclusion in the company's portfolio. It serves as a key performance indicator for the market adoption and commercial viability of the product within the broader biomanufacturing segment. By analyzing this cumulative figure, stakeholders can evaluate the long-term revenue contribution and return on investment for the specific licensed asset.